罗氟司特用于治疗慢性阻塞性肺疾病的效果怎么样？

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent airflow limitation in clinical respiratory medicine. Elderly patients have a higher incidence rate. The exact cause of the disease has not yet been clearly studied, but patients will show clinical symptoms such as chronic cough, sputum production, dyspnea, wheezing, weight loss, anxiety and fatigue, which have a serious impact on the patient's quality of life. Timely and effective clinical treatment can alleviate the progression of the disease and improve clinical symptoms, which has positive significance for patients. Its main functions include inhibiting the activity of inflammatory mediators and leukocyte activation in the body, inhibiting the up-regulation and expression of cell adhesion factors, and inducing cell apoptosis. It also effectively avoids the characteristics of the first-generation PED-4 inhibitors that are prone to severe nausea, vomiting and other adverse reactions. It has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the treatment of COPD. So, how effective is roflumilast in treating chronic obstructive pulmonary disease?

160 patients with chronic obstructive pulmonary disease were selected as the research subjects and randomly divided into an observation group and a control group, with 80 cases in each group. The control group was treated with conventional treatment + doxofylline, and the observation group was given oral treatment with roflumilast on the basis of the control group. Both groups were treated for 1 month. After the course of treatment, the total therapeutic efficiency of the two groups of patients was compared.

Results: After the course of treatment, the total effective rate of treatment in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). From this, it was concluded that roflumilast combined with doxofylline has a definite effect in treating chronic obstructive pulmonary disease, and can significantly improve lung function and reduce inflammatory reactions, which deserves clinical attention.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.